<DOC>
	<DOCNO>NCT01158248</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , panitumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving panitumumab cisplatin together pelvic radiation therapy may effective treat patient cervical cancer . PURPOSE : This phase II trial study side effect give panitumumab cisplatin together pelvic radiation therapy treat patient stage IB , stage II , stage III cervical cancer .</brief_summary>
	<brief_title>Panitumumab , Cisplatin , Pelvic Radiation Therapy Treating Patients With Stage IB , Stage II , Stage III Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess activity concurrent panitumumab cisplatin chemoradiotherapy patient stage IB-IIIB , KRAS-wild type ( KRAS^wt ) cervical cancer , term progression-free survival 4 month MRI accord RECIST criterion . - To assess rate skin toxicity ( e.g. , photosensitivity , acneiform rash , dermatitis ) CTCAE grade 4 and/or gastrointestinal toxicity ( comprise grade gastrointestinal perforation ; leakage stomach , small intestine , colon , rectum , elsewhere peritoneal cavity occur first application study treatment immediately related surgical procedure ) 4 month , regimen patient . Secondary - To assess activity regimen KRAS^wt-positive -negative patient , term overall response rate 4 month . - To assess activity regimen KRAS^wt-positive -negative patient , term progression-free survival 12 month 24 month . - To assess activity regimen KRAS^wt-positive -negative patient , term overall survival 12 month 24 month . - To assess rate severe adverse event regimen patient KRAS^wt KRAS-mutant gene status 4 month . - To assess rate post-treatment severe adverse event 12 month 24 month . - To assess rate severe adverse event panitumumab monotherapy day 14 . OUTLINE : This multicenter study . Patients receive panitumumab IV day 1 , 14 , 29 , 43 cisplatin IV day 14 , 22 , 29 , 36 , 43 , 50 absence disease progression unacceptable toxicity . Patients undergo concurrent external-beam intracavitary radiotherapy ( teletherapy pelvis high-dose rate brachytherapy ) accord treat center specific standard . Blood tissue specimen collect periodically laboratory analysis . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cervical cancer , include follow subtypes : Squamous smallcell largecell carcinoma Adenosquamous cell carcinoma Adenocarcinoma Keratinizing nonkeratinizing carcinoma Stage IBIIIB disease No paraaortic lymph node metastases clinical indication paraaortic field irradiation No predominant clinically effective neuroendocrine tumor cell differentiation PATIENT CHARACTERISTICS : WH0 performance status 02 Serum creatinine clearance &gt; 50 mL/min No prior current malignancy within past 5 year except adequately treat nonmelanoma skin cancer carcinoma insitu cervix No acute lifethreatening vaginal hemorrhage ( require emergency irradiation RBC transfusion ) PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical small cell carcinoma</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>